

## ACCEPTED VERSION

Joanne Milverton, and Drew Carter

### **Neglected impacts of patient decision-making associated with genetic testing**

International Journal of Technology Assessment in Health Care, 2022; 38(1): e75-1-e75-4

© The Author(s), 2022. Published by Cambridge University Press.

Originally published at <http://dx.doi.org/10.1017/S0266462322000575>

Accepted Manuscripts can be made accessible under a [Creative Commons CC-BY-NC-ND](#)

#### PERMISSIONS

<https://www.cambridge.org/core/services/open-access-policies/open-access-journals/green-open-access-policy-for-journals>

### Green Open Access Policy (Version 2)

#### What authors may post to websites and when

Version of manuscript	Personal web page	Department, <b>institutional</b> , or non-commercial subject <b>repository</b>	Commercial repository or social media site
<b>Preprint, SMUR</b>	Entire article, at any time	Entire article, at any time	Entire article, at any time
<b>AM</b> (for science, technical and medical journals)	Entire article, on acceptance	Entire article, 6 months after publication	Abstract only, plus link to VoR on cambridge.org, at any time
<b>AM</b> (for humanities and social science journals)	Entire article, on acceptance	Entire article, on acceptance	Abstract only, plus link to VoR on cambridge.org, at any time
<b>VoR</b>	Abstract only, plus link to VoR on cambridge.org, at any time	Abstract only, plus link to VoR on cambridge.org, at any time	Abstract only, plus link to VoR on cambridge.org, at any time

Again, some journals have more permissive policies than our standard policy. You can view exactly what each journal allows in [this spreadsheet](#).

### Changes from our Green OA policy Version 1

Our policy Version 2 has one substantial change: Accepted Manuscripts of articles where the Version of Record is not fully open access (Gold OA) can now be made publicly accessible under a [Creative Commons CC-BY-NC-ND](#) license.

**3 May 2023**

<http://hdl.handle.net/2440/136784>

## Title Page

NEGLECTED IMPACTS OF PATIENT DECISION MAKING ASSOCIATED WITH GENETIC TESTING

## Running title

Impacts of genetic testing neglected in HTA

Joanne Milverton (corresponding author)

Ms Joanne Milverton  
Senior Health Technology Assessment (HTA) Analyst  
Adelaide Health Technology Assessment (AHTA)  
School of Public Health  
The University of Adelaide  
Level 4, 50 Rundle Mall Plaza  
Adelaide, South Australia  
CRICOS Provider Number 00123M  
Ph +61 8313 1667  
Email: [joanne.milverton@adelaide.edu.au](mailto:joanne.milverton@adelaide.edu.au)

Drew Carter

Dr Drew Carter  
Research Fellow (Ethics)  
Adelaide Health Technology Assessment (AHTA)  
School of Public Health  
Mail Drop DX650 545  
The University of Adelaide, AUSTRALIA 5005  
CRICOS provider code 00123M  
Ph : +61 8 8313 0620  
e-mail: [drew.carter@adelaide.edu.au](mailto:drew.carter@adelaide.edu.au)  
web: <http://researchers.adelaide.edu.au/profile/drew.carter>

## Abstract 100-250 WORDS

We highlight non-health-related impacts associated with genetic testing (GT) and knowing one's genetic status so that HTA analysts and HTA audiences may more appropriately consider the pros and cons of GT. Whereas *health-related* impacts of GT (e.g., increased healthy behaviours and avoidance of harms of unnecessary treatment) are frequently assessed in HTA, some *non-health-related* impacts are less often considered and are more difficult to measure. This presents a challenge for accurately assessing whether a genetic test should be funded.

In health systems where HTA understandably places emphasis on measurable clinical outcomes, there is a risk of creating a GT culture that is pro-testing without sufficient recognition of the burdens of GT. There is also a risk of not funding a genetic test that provides little clinical benefit but nonetheless may be seen by some as autonomy enhancing. The recent development of expanded HTA frameworks that include ethics analyses helps to address this gap in the evidence and bring awareness to non-health-related impacts of GT. The HTA analyst should be aware of these impacts, choose appropriate frameworks for assessing genetic tests, and use methods for evaluating impacts. A new reporting tool presented here may assist in such evaluations.

### Key Words

Genetic testing

Decision making

Benefits and harms

Autonomy

### Acknowledgments and sources of funding

None to declare

### Conflicts of interest

The authors declare that they have no conflicts of interest.

(COI forms to be uploaded to ScholarOne Manuscripts at the time of submission)

## Introduction

Genetic testing (GT) has become commonplace in healthcare and is likely to become even more so in the future (1, 2). The impacts of GT vary depending on whether the test is for screening, diagnosis, or prognosis (i.e., predictive testing). The high accuracy of diagnostic and prognostic testing for germline variants makes them particularly impactful. GT requires careful consideration on the part of providers and evaluators because results can affect not just the individual being tested, but also their offspring and other living relatives (3, 4). GT can also produce impactful incidental findings, namely findings unrelated to the initial purpose of testing. This article aims to highlight some negative impacts of diagnostic and prognostic GT for germline variants for people given an option of GT. The highlighted impacts apply to both genetic testing (analysis of one gene) and genomic testing (analysis of all genes), and some may be greater in the case of genomic testing, for instance with increased possibilities of incidental findings. The impacts highlighted in this article can be both under-acknowledged and difficult to assess as part of health technology assessment (HTA), but are worthy of consideration for the progress of HTA methodology.

The task of the HTA analyst is to determine the benefits, harms and costs of a health technology in the process of advising funders and users on its value for money, while also trying to understand how patients experience the value of the technology (5). GT impacts can be classified as health-related or non-health-related. For example, some writers discuss enhanced autonomy and enhanced equity as positive impacts (benefits) of GT (6). These impacts can be considered *non-health-related* (and also called psychosocial, family or societal effects). These contrast with *health-related* impacts, which may include benefits such as increased healthy behaviours (7) and avoidance of the harms of unnecessary treatment (6). Many health-related impacts of GT have been objectively measured with success (8, 9), but non-health-related impacts are typically harder to measure and are considered less often by the HTA analyst (1, 10). For example, it is difficult to measure

the effects of GT on autonomy, which can be positive, negative or not clearly either, and which can change over time.

Equity refers to “the fair allocation of resources or treatments among different individuals or groups, such that they each get what they are owed or what they are entitled to” (11).

Meanwhile, autonomy refers to the general ability and right of individuals to direct their own lives and to freely make their own informed decisions. For example, one’s autonomy can be enhanced by finding out one’s genetic status when the information is deemed relevant to self-understanding or decision making about one’s health or future (12).

Genetic information is sometimes assumed to be an unqualified good by increasing the information available to you, but things are not so straightforward. In many instances, there may be clear benefits in getting a genetic test. For example, GT may direct your cancer treatment, inform your reproductive planning, or lead to you making helpful lifestyle decisions. However, we highlight some negative non-health-related impacts associated with GT and knowing one’s genetic status to argue that non-health-related impacts should be assessed more carefully by the HTA analyst when weighing the benefits and harms of a genetic test.

#### [The burden of decision making associated with genetic testing](#)

Decision making is an inherent component of genetic and genomic testing for germline variants. However, there is unlikely to be a single decision. Because of the inheritability of germline variants, there is more likely to be a cascade of decisions that follow a genetic test result, especially a positive result (4). You may be faced with decisions such as: whether to tell your children of a test outcome, and at what age; whether to tell other relatives; how to tell them; whether to purchase life insurance; whether to make or change particular plans for the future; and whether to terminate a pregnancy in the case of a positive test result

relating to the fetus. An incidental finding, such as unexpected paternity or health risks, can introduce even more decision making.

Deciding whether to pass GT information onto others can be difficult. One cannot assume that to pass the information on simply increases the autonomy of genetic relatives by giving them the option of getting tested. The same relatives may feel that, being informed, they have lost autonomy, as they now have the knowledge of a genetic variant of concern in their family and will never have the option to not know. There is a tension between the autonomy gained and lost by the same genetic information, creating a burden for the tested individual (13, 14), in that they must decide whether to bring the knowledge of serious disease risk to their family or to leave them unaware to get on with their lives, which may in fact never be impacted by the genetic variant of concern. If the tested individual decides to share information with relatives, those relatives will go on to make further decisions, some of which may lead to bad outcomes, for which the first-tested individual may feel some responsibility. This burden of decision making may be a source of psychological distress or harm.

#### *Measuring the burden of decision making*

In the scientific literature, decision making around GT is extensively discussed within specific disease contexts. Writers discuss who is making decisions, how, and with what reasoning (14-19). But the specific burden of decision making for the individual or what it means for the health service is typically not pinpointed, which makes assessment difficult for the HTA analyst.

One approach used to assess the impact of decision making is to include it in general discussion of anxiety and distress associated with GT. For example, Castellani et al. (15) list “complex and confusing decision making” amongst disadvantages of cystic fibrosis carrier screening. Cicero et al. (20) find that individuals experience “a moderate level of

psychological distress” before counselling for GT for hereditary breast cancer. But studies do not tend to evaluate the burden of decision making specifically, despite acknowledging its psychological effects. Specific instruments to evaluate decision making burden, which could be useful to HTA analysts, are scarce, although one instrument assessing decision fatigue in a health care setting has the potential to be adapted to a diagnostic context (21). Articles that evaluate decision aids in GT contexts may also provide some guidance in designing a tool to measure decision making burden in future (22, 23). The reason we highlight this is not to encourage paternalistically sparing people the burden of complex decision making, but to raise awareness of impacts when it comes to evaluating the benefits and harms of GT as part of HTA.

#### The option of not testing

To avoid the decision making cascade, a person can choose not to use a genetic test, but many people may find this difficult. Within a family, choice is arguably never completely free of influence, and one’s choice does influence someone else’s autonomy (18). Moreover, in the social environment of advanced economies, where more information is generally assumed to be an unqualified good, it may be difficult to opt out of the information loop (19, 24). But choosing not to undertake GT spares a person the negative non-health-related impacts associated with GT and knowing one’s genetic status, which go beyond the burden of decision making. In particular, authors highlight the potential harms of predictive testing in children, including damage to a child’s self-esteem, increase in stigma related anxiety, and discrimination against the child in education, employment and insurance (13, 25).

Despite the potential harms of GT, those who choose to not get tested in family groups are often frowned upon. For example, in a kinship group at risk of Lynch Syndrome, the group members who opted against GT tended to be ostracised, were thought to lack courage, and were sometimes asked to justify their decision (18). Although acknowledging the right to not



know, families tend to consider members who opt against GT as irresponsible or having their “head in the sand” (14, 18), which creates familial tension or rupture.

*Comparing benefits and harms for people who choose GT and people who choose not to test*

There are some examples of helpful comparison when it comes to psychosocial impacts. In particular, Lammens et al. (16) conducted a study to evaluate GT uptake and the psychosocial impact of undergoing or not undergoing GT for Li-Fraumeni Syndrome (LFS). They used the Impact of Event Scale (IES) to measure LFS-specific psychological distress and the Short-form 36 (SF-36) and an adapted version of the Cancer Worry Scale to assess psychosocial impacts for family members at fifty percent or greater risk of being carriers of LFS when offered GT. There are few treatments available to people testing positive for LFS; therefore, the motives of individuals choosing whether or not to get tested may be expected to be largely based on the value of knowing, unrelated to a possible health benefit. The study found that, following genetic counselling, fifty-five percent of participants took up GT. Some motives for not taking up GT were: wanting to avoid problems obtaining a mortgage or life insurance, fearing the result, and seeing no advantage in the genetic test. The analysis of psychosocial impact measured by the tools found that there were similar levels of LFS-related distress in both those who chose to get tested and those who chose not to, and the SF-36 results showed that there was a comparable quality of life between those who were carriers, non-carriers, and those at risk (not tested).

This provides an example of how the benefits and harms of GT versus no GT may be compared in quantitative terms when there is no measureable health-related benefit. A genetic test result may be valued by some people, though not all, simply in terms of the value of knowing (26). Simply knowing is seen by some as autonomy enhancing, and in many cases this may only be presented in qualitative terms. HTA analysts should be aware of the need to assess the value of knowing and incorporate it into GT contexts where little health

benefit is offered by being tested, and they should emphasise the need for genetic counselling.

### The need for empirical evidence

Researchers observe that empirical evidence is needed to compare non-health-related benefits and harms, while conceding that measuring these is impeded because, for instance, families can reason differently about the benefits and harms of GT (owing to different cultural and social contexts, say) (13). Non-health-related impacts are also not obviously measurable in clinical trials, or even observational studies. New frameworks for HTA have only begun to address this problem.

A recent review of the frameworks used to assess genetic tests in HTAs found that the majority of frameworks (twenty two of twenty nine frameworks identified; seventy six percent) include an ethical, legal, and social impact (ELSI) component (1). The most common framework used was the ACCE Framework (named for its components: analytic validity, clinical validity, clinical utility, ethical, legal and social implications). However, only two (the Expanded ACCE and the HTA Susceptibility Test) of the frameworks assessed evidence of the direct experiences of patients and other affected individuals, such as evidence collected via surveys or qualitative studies. Other frameworks extended the concept of clinical utility to personal utility, which can include a broad range of personal impacts such as improved understanding of the disease and more informed reproductive decisions (ACHDNC, Complex Diseases). In spite of these frameworks existing, Pitini et al. argue that the ELSI components of a HTA report are less likely to influence the final funding decision than the technical components quantifying safety, effectiveness and cost-effectiveness (1).

It marks an improvement on past HTA practice to see these expanded evaluations include consideration of some of the non-health-related impacts of GT. HTA analysts should take care to choose an appropriate framework when conducting an evaluation of a genetic test.

Our own HTA group (Adelaide Health Technology Assessment) uses the EUnetHTA HTA Core Model (27) as a framework for writing HTAs in the new HTA *Guidelines for preparing assessments* (28) for the Australian Department of Health. The *Guidelines* also highlight the need to consider the “value of knowing” a genetic test result and social and organisational issues, such as how funding for the genetic test may affect carers or regional populations (i.e., in terms of service access) (28).

#### *Presenting a summary of the evidence*

A new approach may be useful to present a summary of the evidence on non-health-related impacts in a HTA report (see Table 1). Table 1 serves two functions – firstly to summarise the potential non-health benefits and harms of choosing GT or no GT discussed so far, and secondly to provide a reporting tool for HTA. The table provides a novel visual comparison of impacts between people who undergo testing and people who choose not to. Table 1 summarises the evidence in a hypothetical scenario where an extended family is offered GT for a late-onset disease with variable penetrance. The first two columns list some possible non-health-related impacts grouped into what can be presumed to be benefits and harms prior to evaluation. The third column represents the actual impacts on the people who choose to undergo GT, and whether those impacts are positive (highlighted green) or negative (highlighted red). Amber highlight represents a tension between positive or negative impacts, or a neutral impact. In the fourth column, positive and negative impacts on the people who choose not to undergo GT are represented for comparison with the people who underwent GT. The HTA evaluator will need to make a considered judgment informed by the relevant literature to populate the coloured cells. By presenting a visual summary of evidence that has not always been easily highlighted, this novel reporting tool may assist in giving the ELSI component a greater influence on funding decisions, where warranted.

### **Table 1 Reporting tool for non-health-related impacts of genetic testing**

There is research on how patients can value a technology for reasons that do not relate to health gains, but there are still methodological gaps for measuring such dimensions of value (29). HTA analysts should note that not all outcomes are being measured currently in empirical studies (for example, implications for autonomy are not being measured). If measurement is not possible, then these outcomes should at least be discussed in the HTA report. In future, evaluators should increase their awareness of non-health-related impacts of GT reported in studies, choose appropriate frameworks to assess them, and find rigorous methods for assessing them. HTA understandably places emphasis on measurable clinical outcomes, but there is the risk of a scenario where a genetic test is funded because it offers a clinical benefit at a reasonably low cost despite there being other, difficult-to-measure outcomes such as burdens associated with complex decision making and harms that can be avoided by choosing not to get tested. It is also possible that funding the genetic test will itself result in more testing (due to default bias on the part of patients and practitioners, for instance), thus creating a culture around GT that is pro-testing and insufficiently apprised of the burdens and potential harms of GT. The other possibility is that a genetic test may provide no health-related benefit but still warrant funding in how it enhances autonomy for some people.

### **Conclusions**

By highlighting the burdens of complex decision making associated with GT, and the potential harms that can be avoided by choosing not to undertake GT, we have endeavoured to raise awareness of hard-to-measure non-health-related outcomes. Awareness of these outcomes should help the HTA analyst to choose suitable evaluation methodologies and reporting frameworks, such as the novel reporting tool that we present in this article. In turn, this should help the audience for HTAs (funders, clinicians and genetic counsellors) to appropriately consider the pros and cons of GT.



## References

1. Pitini E, De Vito C, Marzuillo C, D'Andrea E, Rosso A, Federici A, et al. How is genetic testing evaluated? A systematic review of the literature. *Eur J Hum Genet.* 2018;26(5):605-15.
2. Wysocki K, Osier N. Direct to consumer versus clinical genetic testing. *J Am Assoc Nurse Pract.* 2019;31(3):152-5.
3. Postolica R, Chirica V, Negura L, Azoicai D, Gavrilovici C. RESPECT FOR CONFIDENTIALITY IN GENETIC TESTING: RIGHT OR BURDEN? *Social Research Reports.* 2015;27:77-87 [PubMed](#) .
4. Emery J. Is informed choice in genetic testing a different breed of informed decision-making? A discussion paper. *Health Expect.* 2001;4(2):81 [PubMed](#) -6.
5. Garrison L, Mestre-Ferrandiz J, Zamora B. The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics. Office of Health Economics Research. 2016.
6. Gil-Arribas E, Herrero R, Serna J. Pros and cons of implementing a carrier genetic test in an infertility practice. *Curr Opin Obstet Gynecol.* 2016;28(3):172-7.
7. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. *Cancer Epidemiol Biomarkers Prev.* 2013;22(10):1687-97.
8. Kessels SJM, Morona JK, Mittal R, Vogan A, Newton S, Merlin T. Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. International HTA Database. 2015.
9. Newton S, Schubert C, Morona J, Fitzgerald P, Merlin T. Genetic testing for hereditary mutations in the RET gene. International HTA Database. 2013.
10. Wade CH, Wilfond BS, McBride CM. Effects of genetic risk information on children's psychosocial wellbeing: a systematic review of the literature. *Genet Med.* 2010;12(6):317 [PubMed](#) -26.
11. HTA Glossary. health technology assessment [htaglossary.net](http://htaglossary.net): INAHTA, HTAi; [Available from: <http://htaglossary.net/HomePage>].
12. Fulda KG. Ethical issues in predictive genetic testing: a public health perspective. *Journal of Medical Ethics.* 2006;32(3):143-7.
13. Manzini A, Vears DF. Predictive Psychiatric Genetic Testing in Minors: An Exploration of the Non-Medical Benefits. *Journal of Bioethical Inquiry.* 2018;15(1):111-20.
14. Hildt E. Predictive Genetic Testing, Autonomy and Responsibility for Future Health. *Medicine Studies.* 2009;1(2):143-53.
15. Castellani C, Macek M, Jr., Cassiman JJ, Duff A, Massie J, ten Kate LP, et al. Benchmarks for cystic fibrosis carrier screening: a European consensus document. *J Cyst Fibros.* 2010;9(3):165-78.
16. Lammens CR, Aaronson NK, Wagner A, Sijmons RH, Ausems MG, Vriends AH, et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. *J Clin Oncol.* 2010;28(18):3008-14.
17. Cypowyj C, Eisinger F, Huiart L, Sobol H, Morin M, Julian-Reynier C. Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives. *Psychooncology.* 2009;18(2):209-15.
18. Cowley L. What can we Learn from Patients' Ethical Thinking about the right 'not to know' in Genomics? Lessons from Cancer Genetic Testing for Genetic Counselling. *Bioethics.* 2016;30(8):628-35.
19. Nicholls SG, Wilson BJ, Etchegary H, Brehaut JC, Potter BK, Hayeems R, et al. Benefits and burdens of newborn screening: public understanding and decision-making. *Per Med.* 2014;11(6):593-607.

20. Cicero G, De Luca R, Dorangricchia P, Lo Coco G, Guarnaccia C, Fanale D, et al. Risk Perception and Psychological Distress in Genetic Counselling for Hereditary Breast and/or Ovarian Cancer. *J Genet Couns.* 2017;26(5):999-1007.
21. Hickman RL, Jr., Pignatiello GA, Tahir S. Evaluation of the Decisional Fatigue Scale Among Surrogate Decision Makers of the Critically Ill. *Western journal of nursing research.* 2018;40(2):191-208.
22. Reumkens K, Tummers MHE, Gietel-Habets JGG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, et al. The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study. *Fam Cancer.* 2019;18(1):137-46.
23. Williams L, Jones W, Elwyn G, Edwards A. Interactive patient decision aids for women facing genetic testing for familial breast cancer: a systematic web and literature review. *Journal of evaluation in clinical practice.* 2008;14(1):70-4.
24. Kater-Kuipers A, de Beaufort ID, Galjaard RH, Bunnik EM. Rethinking counselling in prenatal screening: An ethical analysis of informed consent in the context of non-invasive prenatal testing (NIPT). *Bioethics.* 2020;34(7):671-8.
25. Borry P, Shabani M, Howard HC. Is There a Right Time to Know?: The Right Not to Know and Genetic Testing in Children. *Journal of Law, Medicine and Ethics.* 2014;42(1):19-27.
26. Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. *Health Economics.* 2012;21(3):238-51.
27. EUnetHTA. HTA Core Model: European Network for Health Technology Assessment; 2021 [Available from: <https://www.eunethta.eu/hta-core-model/>].
28. MSAC. Guidelines for preparing assessments for MSAC. Canberra, Australia: Department of Health; 2021.
29. Garrison LP, Jr., Kamal-Bahl S, Towse A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. *Value Health.* 2017;20(2):213-6.

**Table 1 Reporting tool for non-health-related impacts of genetic testing<sup>a</sup>**

Presumed benefit or harm	Non-health-related domain	Possible impacts	
		Underwent GT	Chose no GT
Benefit	Autonomy	Autonomy gained and lost	Autonomy gained and lost
	Equity	No change at time of testing	No change at time of testing
	Knowledge of genetic status <sup>b</sup>	High value	Low value
Harm	Decision making cascade	High burden	No burden
	Discrimination <sup>c</sup>	Increased discrimination	No increase
	Self-esteem	Reduced self esteem	No reduction
	Worry about the future	Increased worry about the future	No increased worry
	Family acceptance	Not ostracised by family	Ostracised by family

**Notes:** a. The coloured cells reflect impacts in a hypothetical example only. The tool comprises the headings in the uncoloured cells, and can be adapted to represent a range of non-health-related impacts in a health technology assessment.

b. The value of knowing can include impacts on career or finance planning, reproductive planning, or understanding one's future health care needs.

c. For example, discrimination in education or employment when genetic status is known.

**Key:** Green = positive impact (benefit); Red = negative impact (harm); Amber = A tension between positive and negative impacts, or a neutral impact.